Running a successful research program is analogous to running a business. Both rely on invention, teamwork, and a good reputation to succeed, but few young researchers are equipped to lead their teams when they embark on independent careers. One such seasoned professional who advanced his leadership skills early in his career in the realm of clinical research is Dr. Pramod Kashid. Dr. Kashid is clinical research professional who holds a master’s degree in pharmacy and a Ph.D. in pharmaceutical science from NMIMS University, Mumbai. He is further pursuing an MBA at Said Business School, the University of Oxford, UK. On the professional front, Dr. Kashid started his career in 2004 as a CRA in one of the topmultinational pharmaceutical companies. Later, he joined Syneos Health (formerly INC Research), a global clinical research organization in India, where he managed the clinical research associates team and projects in India and the Asia Pacific region. Pramod had the opportunity to establish clinical operation team for a global business unit in Australia, Philippines, Indonesia, Singapore, China, Hong Kong, Thailand, and India while working at INC Research. In addition, Pramod pursued a regional opportunity in 2014 with PRA Health Science (presently ICON), a top 10 global CRO based in Singapore, where he managed global clinical research projects.

Currently, Dr. Pramod Kashid is working as a Senior Director for clinical trial management at Medpace, one of the leading clinical research organizations founded in 1992 and

publicly listed on the NASDAQ in 2016 as Medpace Holdings Inc. Medpace is a full service clinical research organization(CRO)that provides Phase I-IV clinical development services to biotechnology, pharma ceutical, and medical device companies. Moreover, the company is known for making complex drug development process seamless through its global presence, scientific and medical expertise and full service delivery model with therapeutic focus. Medpace is also known for additional services like central laboratory, Bioanalytical and Imaging & ECG core Laboratories. Medpace’s unique global partnering concept places a strong emphasis on clinical research as well as the highest ethical standards and work performance. Its specialist teams work as an extension of their client’s teams, engaging promptly and providing strategic thinking to ensure faster startup times, greater quality, and the most efficient delivery of the clinical trial at every stage.

The need to get new medicine in the market and helping mankind to live longer and healthier lives is the key aspect that drive dr. Pramod kashid towards the purpose

Dr. Kashid joined Medpace in 2018 with the aim to expand the team in the Asia Pacific region, particularly for clinical project management group. His role at Medpace is ranged from providing oversight on global clinical research projects for novel drugs in the Asia Pacific region, strengthening the team maintaining staff retention to assisting the company in expanding its business as well.“Our aim as the name indicates, is to bring medicine to market faster and more seamlessly, without adding complexity to the process” signifies Dr.Kashid.

Over the years, Medpace has spread its footprints across the globe in more than 40 countries and has been listed as America’s best midsize company in 2021 and 2022 by Forbes Magazine. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics by leveraging local regulatory and deep therapeutic expertise across all major areas, including oncology, cardiology, metabolic disease, endocrinology, central nervous system, and antiviral and anti-infective therapies. Dr. Kashid concludes “The clinical research future appears to be more dependent technology evaluation and adapting more patient centric approach by implementing decentralized trial solutions while maintaining traditional clinical trial management process to ensure regulatory compliance and patient safety. Further, real world data and blockchain technology will have a greater impact on future drug development , allowing for more efficiency and effective medicine to reach the market faster than in the past.”